The Cooper Companies (COO) 44th Annual J.P. Morgan Healthcare Conference summary

Business overview and market position

• Operates globally in vision care and women's health, with products in over 130 countries and 15,000+ employees.

• Two main units: global leader in contact lenses and a top fertility/women’s healthcare business.

• Contact lens division leads in global wearers and is second in revenue; fertility business is a non-pharma device leader.

• Over 50 million users globally, with 42 million annual contact lens wearers.

• Contact lens business generates about two-thirds of total revenue, with strong geographic diversification.

Financial performance and guidance

• FY25 revenue reached $4.1B; FY26 guidance: $4.299–$4.338B (4.5–5.5% organic growth); Q1 2026: $1.019–$1.030B.

• 10-year revenue CAGR: 8.6% overall, 16% for fertility, 6–6.3% for contact lenses.

• Double-digit EPS growth targeted, with non-GAAP EPS of $4.45–$4.60 for the year.

• Free cash flow projected at $575–$625 million, with a multi-year target of $2.2 billion+.

• Share buybacks prioritized, with a $2 billion repurchase plan and ~2/3 of FY26 FCF allocated to buybacks.

Strategic priorities and operational changes

• Focus on organic growth, product innovation, and disciplined capital allocation.

• Completed major ERP upgrades and consolidated back office operations for cost synergies.

• AI and digital tools are being leveraged for inventory and operational efficiency.

• Headcount will remain flat, with ongoing efficiency initiatives.

• Fostering a strong culture and long-term value creation.